Biosimilar SB17 versus reference ustekinumab in moderate to severe plaque psoriasis after switching: phase 3 study results up to week 52
SB17 demonstrated clinical biosimilarity to UST after switching from UST, and maintained long-term comparable efficacy and safety with UST up to Week 52.
Authors
- Steven R. Feldman (ORCID: https://orcid.org/0000-0002-0090-6289)
- Giampiero Girolomoni (ORCID: https://orcid.org/0000-0001-8548-0493)
- Jan Brzezicki
- Д. Г. Рекалов (ORCID: https://orcid.org/0000-0002-5793-2322)
- Grażyna Pulka
- Elżbieta Kłujszo
- Joanna Narbutt (ORCID: https://orcid.org/0000-0002-8135-012X)
- Jiyoon Lee (ORCID: https://orcid.org/0000-0001-7984-7084)
- Min-Kyung Lee (ORCID: https://orcid.org/0000-0002-8248-9852)
- Nataliya Reznichenko (ORCID: https://orcid.org/0000-0002-1401-947X)
- Magdalena Dmowska-Stecewicz
- Young Hee Rho
- Maria Agnieszka Zegadło-Mylik
- Lidia Rajzer
Institutions
- University of Verona (IT)
- Samsung (South Korea) (KR)
- University of Siedlce (PL)
- Centrum Badań Jakości (PL)
- Międzyleski Szpital Specjalistyczny w Warszawie (PL)
- Wake Forest University (US)
Publication Details
- Journal
- Journal of Dermatological Treatment
- Published
- 2024-12-10
- DOI
- https://doi.org/10.1080/09546634.2024.2436607
- Citations
- 6
- Primary Topic
- Biosimilars and Bioanalytical Methods
- Type
- article
- Field-Weighted Citation Impact
- 1.44